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Available online 26 November 2015The Genea042 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, through ICM outgrowth on inactivated human feeders. The line showed pluripotent cell morphology
and genomic analysis veriﬁed a 46, XX karyotype and female allele pattern through traditional karyotyping, CGH
and STR analysis. Pluripotency of Genea042was demonstratedwith 81% of cells expressingNanog, 95% Oct4, 53%
Tra1-60 and 97% SSEA4, a PluriTest Pluripotency score of 30.06, Novelty score of 1.24 and Alkaline Phosphatase
activity. The cell line was negative for Mycoplasma and any visible contamination.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).St
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ontact person and email biljana.dumevska@geneabiocells.com
ate archived/stock date March, 2009
rigin Human Embryos
ype of resource Derived human embryonic stem cell line
ub-type Human pluripotent cell line
ey marker expression Nanog, Oct4, Tra1-60, and SSEA4
uthentication Identity and purity of cell line conﬁrmed
(Figs. 1–6 below)
nk to related literature (direct
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http://www.ncbi.nlm.nih.gov/pubmed/
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UK Stem Cell Bank (UKSCB) registered
SCSC14-40
SNP Data GEO accession numbers GSM638444thical Approval Obtained from the Genea Ethics Committee on
21 February 2001 under the Australian Na-
tional Health and Medical Research Council
(NHMRC) licence 309,703Resource detailsate of derivation February 2009
aryotype 46, XX – no abnormalities detected
ex Female
luripotent YES - by Alkaline Phosphatase stain positivity, Nanog, Oct4,
Tra1-60, and SSEA4 staining and PluriTest
isease status Unaffected. This is an open access article under theerilityCC BY-NC-ND licenseThe cell line is tested and found negative for Mycoplasma
and any visible contaminationbling lines available YES - GENEA043 (XY NIHhESC-13-0232, SCSC14-40)SiMaterials and methods
Cell line derivation
The embryo was plated whole onto mitomycin C inactivated Detroit
510 HFF human feeders (plated 90,000 cells 1 well of 4 well – 47,368
cells/cm2) in 20% Knock out serum in standard hESC culture medium
with 20 ng/mL Fgf2 (Amit et al., 2000) and 100 ng/mL GMCSF (R&D
Systems #215-GM). CGH karyotyping and STR proﬁling was performed
at the ﬁrst cryobanking step from ICM outgrowths maintained on
feeders. Alkaline Phosphatase staining was performed on feeders. Cells
were then enzymatically passaged as single cells in M2 pluripotent
cell maintenance medium (Genea Biocells) and CGH/karyotyping re-
peated, immunoﬂuorescent pluripotent marker staining, PluriTest and
sterility testing performed.
Genetic analysis
1. Karyotyping: Passage 4; For enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/ml colcemid
(Invitrogen) and 37.5 g/ml BrdU (Sigma) for 17–19 h or 5 ng/ml
colcemid for 2.5 h. Single cells were subsequently obtained using
Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred
to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory for
preparation of metaphase spreads and cytogenetic analysis by
G-banding. A minimum of 15 metaphase cells were examined, of
which a full karyotype or chromosome counts was performed for 5
and 10 of the metaphases respectively.(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Brightﬁeld morphology of Genea042 on human inactivated feeders.
Fig. 2. Alkaline Phosphatase staining.
Fig. 3. Kary
Table 1
CGH array summary.
Parameter Result
Sample name Genea042 p8_2
Date reported 7th August 2013
Hybridisation balance A balanced hybridization was observed for all
chromosomes, relative to reference DNA
Copy number change No copy number changes N400 kb were detected
Interpretation Female cell line
319B. Dumevska et al. / Stem Cell Research 16 (2016) 318–3212. Comparative Genomic Hybridisation (CGH) based chromosomal analysis:
Passage 8 (6 on feeders, 2 enzymatic); CGH was used to screen
targeted regions of the genome for gains and losses associated with
chromosomal imbalances such as aneuploidy, deletions and duplica-
tions. CGH was performed using SurePrint G3 microarrays (8 × 60 K
format) which were scanned with the Agilent Scanner C and analysed
using Genomic Workbench Standard Edition 5.0 software (Agilent
Technologies).
3. DNA Proﬁling: Passage 3; DNA ‘ﬁngerprinting’ was performed
using the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied
Biosystems #4,322,288) to provide permanent genetic identiﬁcation
of the cell lines. https://www.thermoﬁsher.com/order/catalog/
product/4322288.
Pluripotency assessment
1. Alkaline Phosphatase: Passage p4; Genea042 grown on feeders were
stained as per manufacturers protocol using the Merck Millipore
Alkaline Phosphatase Detection Kit (SCR004)
2. Immunoﬂuorescence: Passage 17 (15 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560,483 1:200;
Oct4 #560,217 1:150: Tra1-60 #560,121 1:150; SSEA4 #560,308
1:200 (all BD Pharmingen:). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).otype.
Fig. 5. Percentage of cells expressing SSEA4, Nanog, Oct3/4 and Tra1/60 as detected by immunoﬂuorescence.
Fig. 4. STR proﬁle.
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Fig. 6. PluriTest.
321B. Dumevska et al. / Stem Cell Research 16 (2016) 318–3213. PluriTest: Passage 17 (15 on feeders, 2 enzymatic); RNAwas collected
and subjected to a PluriTest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).
Sterility testing
1. Mycoplasma: Passage 14; testingwas performed at the Victorian Infec-
tious Diseases Reference Laboratory using Mycoplasma Genus PCR
2. Microbial contamination: testing was performed in conjunction with
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
freemedium(Genea BiocellsM2medium) for 2–3 days at 37 degrees
celcius. A clear solution at ~48-72 h indicated lack of bacterial, fungal
or yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘Development of human embryonic
stem cells from excess ART embryos’) was obtained from the GeneaEthics Committee on 21 February 2001. Excess ART embryos were
fully consented for stem cell derivation by all responsible people
through an informed consent process (signed de-identiﬁed consent
form can be provided upon request). Donors have received no payment
or ﬁnancial beneﬁts for their donation. Genea042 has been derived from
a donated, fully commercially consented human embryo, originally
created by assisted reproduction technology (ART) for the purpose of
procreation, under Australian National Health and Medical Research
Council (NHMRC) licence 309,703. This licence was issued to GENEA
on 16 April 2004. More information about the licence can be obtained
from the NHMRC webpage at http://www.nhmrc.gov.au/health-
ethics/human-embryos-and-cloning/database-licences-authorising-
use-excess-art-embryos.
Morphology
The derived stem cell line, Genea042, morphologically displays
adherent monolayer of compact cells in well-deﬁned colonies
with high nuclear to cytoplasmic ratio and prominent nucleoli
(Fig. 1/Fig. 2).
Genetic analysis
The cell line has been karyotyped (Fig. 3, Supplementary Fig. 1) and
tested by CGH (Table 1, Supplementary Fig. 2), which demonstrated 46,
XX karyotype, consistent with original derivation. Analysis of STR
markers showed Allele pattern consistent with female genotype
(Fig. 4, Supplementary Fig. 3).
Disease status
Unaffected.
Pluripotency
GENEA042 is pluripotent by
1. Alkaline Phosphatase stain positivity (Fig. 2);
2. immunoﬂuorescence with 81% Nanog positive, 95% Oct4 positive,
53% Tra1-60 positive, and 97% SSEA4 positive (Fig. 5A, quantiﬁed
in 5B); and
3. PluriTest with a 30.06 Pluripotency score and 1.24 Novelty score
(Fig. 6).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.11.011.
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